GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
0
c/glp1science·posted 1 year ago by u/noor_hovland

why does nobody talk about gastric emptying

Speculation Clean Column ×1

Trying to get a straight answer on this: why does nobody talk about gastric emptying.

The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.

Was completely wrong about the gastric emptying story in a thread here two years ago. Someone corrected me with a citation and I have not made that mistake since.

Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.

Would rather be corrected in public than confident in private.

0 up / 0 down43% upvoted7 commentsid 1rwfga24 May 2025

7 comments

7 in this archive, depth 4

best — the order this archive was captured in

u/tomas_broberg2 points·1 year ago

Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.

replysharereportpermalink
u/noor_hovlandOP3 points·1 year ago

Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.

replysharereportpermalink
u/split_dose_sceptic1 point·1 year ago

Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.

replysharereportpermalink
u/farid_kuipers1 point·1 year ago

half-life is why these are weekly and not daily

replysharereportpermalink
[removed]1 point·1 year ago

[removed by moderator]

replysharereportpermalink
u/runa_cabrera4 points·1 year ago

the peripheral and central stories are not in competition

replysharereportpermalink
u/aksel_palacios1 point·1 year ago

Are we talking about receptor affinity or clinical potency?

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.